Carboetomidate
CAS: 1257067-10-9
Rif. 3D-FC19713
| 1g | Fuori produzione | ||
| 2g | Fuori produzione | ||
| 100mg | Fuori produzione | ||
| 250mg | Fuori produzione | ||
| 500mg | Fuori produzione |
Informazioni sul prodotto
- 1-[(1R)-1-Phenylethyl]-1H-pyrrole-2-carboxylic acid ethyl ester(R)-Ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate
Carboetomidate is a chemical analog of etomidate, and has been used in the pediatric population as an alternative to etomidate. It has been shown to be effective in patients with metabolic disorders, such as hypoglycemia, hyperglycemia, and hyperammonemia. Carboetomidate is also used in the treatment of acute seizure disorders. The effective dose for carboetomidate is 1-5 mg/kg intravenously or intramuscularly. Side effects include muscle tremors and respiratory depression. Carboetomidate binds to gamma-aminobutyric acid receptors, leading to a decrease in neuronal activity. In rats, it was found that carboetomidate undergoes side-chain cleavage by esterases during metabolism to form a ketone group on the alpha carbon atom of the side chain. This metabolic pathway results in rapid clearance from the body and decreased duration of action.
